CEUFAST COURSE

Hypertension

Contact Hour(s): 2 Contact Hours including 2 Advanced Pharmacology Hours Author: Desiree Reinken (PhD, APRN, NP-C) This peer-reviewed course is applicable for the following professions:Advanced Practice Registered Nurse (APRN), CCI Cred...

Course Summary

Contact Hour(s):  

2 Contact Hours including 2 Advanced Pharmacology Hours 

Author: 

Desiree Reinken (PhD, APRN, NP-C) 

This peer-reviewed course is applicable for the following professions:

Advanced Practice Registered Nurse (APRN), CCI Credentialed Specialists, Certified Nurse Midwife, Certified Nurse Practitioner, Certified Registered Nurse Anesthetist (CRNA), Clinical Nurse Specialist (CNS), Licensed Practical Nurse (LPN), Licensed Vocational Nurses (LVN), Midwife (MW), Nursing Student, Registered Nurse (RN), Registered Nurse Practitioner 

Accreditations:  

The American Nurses Credentialing Center (ANCC)

State Approvals:

Alabama, Provider #ABNP1485; California BRN Provider #CEP # 13509; Kentucky Board of Nursing Provider #7-0085; Florida Board of Nursing Provider 50-353

Course Description: 

This course discusses Hazard Communication methods and purposes in the workplace, including real-life events that can help embed the information. It also has case studies to help learners identify with the materials. This course touches on the history of OSHA over the last 50 years and some of the advocation needs. 

Outcomes: 

≥ 92% of participants will know the differences between the types of hypertension. 

Objectives: 

Upon completion of this course, the participant will be able to meet the following objectives: 

1. Summarize the pathophysiology of hypertension (HTN).

2. Differentiate between the types of HTN. 


3. Identify symptoms of HTN. 


4. Distinguish between the classes of antihypertensives. 


5. Outline the role of non-pharmacological treatments in the management of HTN. 


Disclosures: 

CEUFast Inc. and the course planning team for this educational activity do not have any relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.